See more : Beijing Teamsun Technology Co.,Ltd. (600410.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Sandoz Group AG (SDZNY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sandoz Group AG, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Domo Activos, S.A. (DOMO.MC) Income Statement Analysis – Financial Results
- BankInvest – Danske Aktier KL (BAIDKAA.CO) Income Statement Analysis – Financial Results
- Hubbell Incorporated (HUBB) Income Statement Analysis – Financial Results
- National General Industries Limited (NATGENI.BO) Income Statement Analysis – Financial Results
- Azion Corporation (6148.TWO) Income Statement Analysis – Financial Results
Sandoz Group AG (SDZNY)
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 9.98B | 8.86B | 8.79B | 9.04B |
| Cost of Revenue | 5.42B | 4.71B | 4.64B | 4.88B |
| Gross Profit | 4.56B | 4.15B | 4.15B | 4.16B |
| Gross Profit Ratio | 45.74% | 46.87% | 47.20% | 45.99% |
| Research & Development | 926.00M | 795.57M | 832.90M | 819.41M |
| General & Administrative | 0.00 | 22.50K | 0.00 | 0.00 |
| Selling & Marketing | 2.39B | 0.00 | 0.00 | 0.00 |
| SG&A | 2.39B | 22.50K | 1.94B | 2.00B |
| Other Expenses | 874.00M | 8.60M | 6.40M | 5.63M |
| Operating Expenses | 4.19B | 22.50K | 2.77B | 2.81B |
| Cost & Expenses | 9.60B | 22.50K | 7.41B | 7.69B |
| Interest Income | 31.00M | 7.64M | 4.57M | 2.82M |
| Interest Expense | 202.00M | 84.05M | 61.26M | 70.40M |
| Depreciation & Amortization | 525.00M | 437.42M | 447.08M | 650.46M |
| EBITDA | 857.00M | 1.68B | 1.83B | 1.99B |
| EBITDA Ratio | 8.59% | 0.00% | 20.77% | 22.03% |
| Operating Income | 375.00M | -22.50K | 1.38B | 1.34B |
| Operating Income Ratio | 3.76% | 0.00% | 15.69% | 14.83% |
| Total Other Income/Expenses | -245.00M | -137.00M | -179.20M | -677.68M |
| Income Before Tax | 130.00M | -22.50K | 1.20B | 662.66M |
| Income Before Tax Ratio | 1.30% | 0.00% | 13.65% | 7.33% |
| Income Tax Expense | 50.00M | 361.00 | 368.45M | 227.14M |
| Net Income | 77.00M | -22.86K | 830.15M | 433.64M |
| Net Income Ratio | 0.77% | 0.00% | 9.44% | 4.80% |
| EPS | 0.18 | 0.00 | 1.93 | 1.01 |
| EPS Diluted | 0.18 | 0.00 | 1.93 | 1.01 |
| Weighted Avg Shares Out | 429.90M | 431.00M | 431.00M | 431.00M |
| Weighted Avg Shares Out (Dil) | 431.20M | 431.00M | 431.00M | 431.00M |
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicines Xgeva® and Prolia® EC approval based on robust development program confirming...
Sandoz reports first quarter 2024 sales
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong first quarter performance, with net sales [1] of USD 2.5 billion, up 6% in constant currencies (up 5% in USD) Biosimilar business growing 21% in constant currencies ...
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
All proposals of Board of Directors approved Gilbert Ghostine re-elected as Chairman of Board of Directors; all other Board members standing for election confirmed Mathai Mammen, Graeme Pitkethly and Michael Rechsteiner elected as new Board members Dividend of CHF 0.45...
Sandoz reaches agreement with Amgen over patent dispute
Swiss generic and biosimilar manufacturer Sandoz said on Tuesday it had reached an agreement with U.S. drugmaker Amgen resolving all patent litigation related to its U.S. denosumab biosimilars.
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Agreement clears path for launch of Jubbonti® and Wyost® on May 31, 2025...
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Pyzchiva® approved as one of first ustekinumab biosimilars in Europe EC approval based on robust development program confirming match to reference medicine in terms of safety, efficacy and...
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines
MEDIA RELEASE EUR 50m investment in Kundl plant extension emphasizes commitment to serve more patients with critical antibiotics, produced entirely in Europe Additional manufacturing area of 3,000m2 means Kundl can now manufacture 240 million packages per year Represents capacity increase...
Sandoz reports fourth quarter 2023 sales and full-year 2023 results
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong fourth quarter performance, with net sales1 of USD 2.5 billion, up 10% in constant currencies (up 11% in USD) Full-year 2023 net sales of USD...
Sandoz receives FDA approval for first and only denosumab biosimilars
MEDIA RELEASE Wyost® (denosumab-bddz) and Jubbonti® (denosumab-bddz) interchangeable with and approved by FDA for all indications of reference medicines Xgeva ®* (denosumab) and Prolia®* (denosumab) FDA approval based on robust clinical studies and totality of evidence, which show no clinically...
Sandoz announces nominations to the Board of Directors and leadership change
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Mathai Mammen and Michael Rechsteiner nominated to stand for election to Sandoz Board of Directors at upcoming Annual General Meeting Remco Steenbergen appointed as Sandoz CFO...
Source: https://incomestatements.info
Category: Stock Reports